Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endosonography | 12 | 2016 | 55 | 1.540 |
Why?
|
| Endoscopes, Gastrointestinal | 12 | 2010 | 12 | 0.770 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 6 | 2016 | 29 | 0.610 |
Why?
|
| Endoscopy, Gastrointestinal | 9 | 2013 | 23 | 0.540 |
Why?
|
| Gallbladder Diseases | 2 | 2010 | 8 | 0.530 |
Why?
|
| Cholestasis | 3 | 2012 | 18 | 0.430 |
Why?
|
| Barrett Esophagus | 1 | 2014 | 4 | 0.420 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 23 | 0.410 |
Why?
|
| Biliary Tract Diseases | 3 | 2012 | 12 | 0.400 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 39 | 0.400 |
Why?
|
| Biliary Tract | 2 | 2012 | 7 | 0.390 |
Why?
|
| Catheter Ablation | 1 | 2014 | 113 | 0.380 |
Why?
|
| Lymphangioma, Cystic | 1 | 2012 | 1 | 0.370 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 298 | 0.340 |
Why?
|
| Pancreatic Diseases | 3 | 2009 | 21 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 131 | 0.330 |
Why?
|
| Polyps | 1 | 2010 | 9 | 0.320 |
Why?
|
| Cholecystectomy | 1 | 2010 | 21 | 0.310 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 88 | 0.300 |
Why?
|
| Liver Diseases | 1 | 2009 | 72 | 0.280 |
Why?
|
| Humans | 42 | 2019 | 32284 | 0.280 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2013 | 62 | 0.250 |
Why?
|
| Liver | 1 | 2009 | 491 | 0.240 |
Why?
|
| Intestinal Mucosa | 3 | 2019 | 75 | 0.230 |
Why?
|
| Gastrointestinal Diseases | 5 | 2009 | 51 | 0.230 |
Why?
|
| Liver Failure | 1 | 2005 | 21 | 0.220 |
Why?
|
| Stents | 2 | 2009 | 159 | 0.210 |
Why?
|
| Colonoscopy | 4 | 2019 | 45 | 0.190 |
Why?
|
| Mucins | 1 | 2003 | 16 | 0.190 |
Why?
|
| Respiratory Mucosa | 1 | 2003 | 13 | 0.190 |
Why?
|
| Equipment Design | 11 | 2010 | 177 | 0.190 |
Why?
|
| Sensitivity and Specificity | 5 | 2012 | 555 | 0.180 |
Why?
|
| Epithelial Cells | 1 | 2003 | 137 | 0.180 |
Why?
|
| Catheterization | 3 | 2010 | 55 | 0.170 |
Why?
|
| Device Approval | 2 | 2010 | 6 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2010 | 52 | 0.150 |
Why?
|
| Male | 11 | 2019 | 19434 | 0.150 |
Why?
|
| Endoscopy, Digestive System | 2 | 2009 | 11 | 0.140 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 502 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2008 | 35 | 0.130 |
Why?
|
| Technology Assessment, Biomedical | 4 | 2009 | 11 | 0.120 |
Why?
|
| Digestive System Diseases | 1 | 2016 | 5 | 0.120 |
Why?
|
| Choledocholithiasis | 1 | 2016 | 4 | 0.120 |
Why?
|
| Intraoperative Care | 1 | 2016 | 52 | 0.120 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2016 | 21 | 0.120 |
Why?
|
| Female | 10 | 2016 | 19954 | 0.110 |
Why?
|
| Endoscopy | 2 | 2019 | 54 | 0.110 |
Why?
|
| Middle Aged | 7 | 2019 | 11843 | 0.100 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2013 | 12 | 0.100 |
Why?
|
| Lymphatic Diseases | 1 | 2012 | 11 | 0.090 |
Why?
|
| Sphincterotomy, Endoscopic | 2 | 2010 | 4 | 0.090 |
Why?
|
| Surgical Instruments | 2 | 2009 | 25 | 0.090 |
Why?
|
| Equipment Safety | 5 | 2010 | 19 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2012 | 114 | 0.090 |
Why?
|
| Adult | 5 | 2016 | 9263 | 0.090 |
Why?
|
| Video Recording | 2 | 2010 | 61 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2010 | 212 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2010 | 25 | 0.080 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2010 | 4 | 0.080 |
Why?
|
| Pancreatitis, Chronic | 1 | 2010 | 8 | 0.080 |
Why?
|
| Gastrostomy | 1 | 2010 | 17 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2008 | 755 | 0.080 |
Why?
|
| Calculi | 1 | 2009 | 1 | 0.080 |
Why?
|
| Gallstones | 1 | 2009 | 11 | 0.080 |
Why?
|
| Microscopy | 1 | 2009 | 27 | 0.070 |
Why?
|
| Cathartics | 1 | 2009 | 5 | 0.070 |
Why?
|
| Hemostasis, Surgical | 1 | 2009 | 11 | 0.070 |
Why?
|
| Disinfection | 1 | 2009 | 6 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2009 | 73 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2009 | 20 | 0.070 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2009 | 13 | 0.070 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 33 | 0.070 |
Why?
|
| Gallbladder Neoplasms | 1 | 2009 | 35 | 0.070 |
Why?
|
| Capsule Endoscopy | 1 | 2008 | 4 | 0.070 |
Why?
|
| Endoscopes | 1 | 2008 | 3 | 0.070 |
Why?
|
| Gastric Mucosa | 1 | 2008 | 15 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2009 | 126 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 358 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 37 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 851 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2008 | 66 | 0.070 |
Why?
|
| Forecasting | 1 | 2008 | 144 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3410 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 164 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2007 | 44 | 0.060 |
Why?
|
| Linoleic Acids, Conjugated | 1 | 2007 | 7 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2007 | 31 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 55 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 24 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2016 | 3612 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 544 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 2238 | 0.060 |
Why?
|
| Prognosis | 1 | 2010 | 1529 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 880 | 0.060 |
Why?
|
| Controlled Clinical Trials as Topic | 3 | 2010 | 9 | 0.060 |
Why?
|
| Body Composition | 1 | 2007 | 327 | 0.060 |
Why?
|
| Health Status | 1 | 2006 | 356 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 220 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 322 | 0.050 |
Why?
|
| United States | 5 | 2010 | 4079 | 0.050 |
Why?
|
| Uridine Triphosphate | 1 | 2003 | 1 | 0.050 |
Why?
|
| Goblet Cells | 1 | 2003 | 4 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2003 | 11 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 2003 | 8 | 0.050 |
Why?
|
| Second Messenger Systems | 1 | 2003 | 8 | 0.050 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2003 | 11 | 0.050 |
Why?
|
| Bronchi | 1 | 2003 | 34 | 0.050 |
Why?
|
| Species Specificity | 1 | 2003 | 98 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2003 | 69 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 109 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 62 | 0.050 |
Why?
|
| Adenosine | 1 | 2003 | 68 | 0.050 |
Why?
|
| Trachea | 1 | 2003 | 53 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 199 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2008 | 1424 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2003 | 119 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2003 | 285 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2016 | 566 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2003 | 821 | 0.040 |
Why?
|
| Diet, Gluten-Free | 1 | 2019 | 3 | 0.040 |
Why?
|
| Obesity | 1 | 2007 | 1108 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 12 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2019 | 86 | 0.040 |
Why?
|
| Neuroendocrine Tumors | 1 | 2019 | 19 | 0.040 |
Why?
|
| Diarrhea | 1 | 2019 | 72 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 115 | 0.040 |
Why?
|
| Child | 2 | 2016 | 2446 | 0.040 |
Why?
|
| Collagen | 1 | 2019 | 229 | 0.030 |
Why?
|
| Needles | 2 | 2009 | 28 | 0.030 |
Why?
|
| Enema | 2 | 2009 | 6 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 394 | 0.030 |
Why?
|
| Mice | 1 | 2003 | 2544 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 3896 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 476 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2016 | 2320 | 0.030 |
Why?
|
| Cholangiography | 1 | 2016 | 12 | 0.030 |
Why?
|
| Animals | 2 | 2010 | 8165 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 505 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2008 | 548 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 906 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 1248 | 0.020 |
Why?
|
| Abdomen | 1 | 2012 | 44 | 0.020 |
Why?
|
| Aged | 2 | 2016 | 10257 | 0.020 |
Why?
|
| Compassionate Use Trials | 1 | 2010 | 3 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2010 | 6 | 0.020 |
Why?
|
| Medical Device Recalls | 1 | 2010 | 2 | 0.020 |
Why?
|
| Current Procedural Terminology | 1 | 2010 | 3 | 0.020 |
Why?
|
| Off-Label Use | 1 | 2010 | 14 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 96 | 0.020 |
Why?
|
| Pancreas | 1 | 2010 | 107 | 0.020 |
Why?
|
| Lasers, Gas | 1 | 2009 | 3 | 0.020 |
Why?
|
| Hemostatics | 1 | 2009 | 13 | 0.020 |
Why?
|
| Syringes | 1 | 2009 | 5 | 0.020 |
Why?
|
| Electrocoagulation | 1 | 2009 | 11 | 0.020 |
Why?
|
| Laser Coagulation | 1 | 2009 | 13 | 0.020 |
Why?
|
| Ligation | 1 | 2009 | 64 | 0.020 |
Why?
|
| Device Removal | 1 | 2009 | 39 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 3521 | 0.020 |
Why?
|
| Dissection | 1 | 2008 | 16 | 0.020 |
Why?
|
| Miniaturization | 1 | 2008 | 5 | 0.020 |
Why?
|
| Fiber Optic Technology | 1 | 2008 | 13 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 39 | 0.020 |
Why?
|
| Total Quality Management | 1 | 2008 | 17 | 0.020 |
Why?
|
| Forms and Records Control | 1 | 2008 | 8 | 0.020 |
Why?
|
| Safety Management | 1 | 2008 | 27 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2008 | 52 | 0.020 |
Why?
|
| Safety | 1 | 2007 | 65 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2008 | 153 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 93 | 0.020 |
Why?
|
| Injections | 1 | 2007 | 72 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 106 | 0.020 |
Why?
|
| Rest | 1 | 2007 | 49 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2006 | 3 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2006 | 7 | 0.020 |
Why?
|
| Occult Blood | 1 | 2006 | 12 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 169 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 236 | 0.020 |
Why?
|
| Energy Intake | 1 | 2007 | 121 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 276 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2006 | 71 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 287 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 136 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2007 | 150 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2006 | 120 | 0.010 |
Why?
|
| Body Weight | 1 | 2007 | 323 | 0.010 |
Why?
|
| Comorbidity | 1 | 2006 | 563 | 0.010 |
Why?
|
| Motor Activity | 1 | 2007 | 332 | 0.010 |
Why?
|
| Mass Screening | 1 | 2006 | 256 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 390 | 0.010 |
Why?
|
| Neoplasms | 1 | 2007 | 763 | 0.010 |
Why?
|